The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Disease Duration, Corticosteroid Use Predict Etanercept Response in JIA

Disease Duration, Corticosteroid Use Predict Etanercept Response in JIA

January 16, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Almost half of juvenile idiopathic arthritis (JIA) patients treated with etanercept achieve minimal disease activity after one year of treatment, according to new findings.

You Might Also Like
  • Can IL-6 Predict Sarilumab Response?
  • Heart Rate Variability to Predict Treatment Response in Patients with RA
  • Methotrexate Halt Feasible in Some Etanercept RA Responders

Younger patients and those who did not require corticosteroid treatment were more likely to have an excellent response, Dr. Kimme Hyrich of the University of Manchester in the UK and colleagues found. They reported their findings online on Dec. 31, 2015, in Rheumatology.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Clinical factors associated with response to anti-tumor necrosis factor therapy in adults with rheumatoid arthritis include lower disease activity and less disability, but few studies have looked at the issue in children, Dr. Hyrich and colleagues note.

To investigate factors associated with etanercept response in a real-world setting, the researchers looked at 496 children and young adults with JIA who were starting etanercept treatment as part of the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At one year, 74% had achieved American College of Rheumatology Pediatric (ACR Pedi) 30; 69% achieved ACR Pedi 50; and 38% ACR Pedi 90, while 48% of patients had minimal disease activity.

Shorter disease duration (odds ratio 0.91), no concurrent corticosteroid use (OR 0.48), and history of uveitis (OR 2.26) were each independently associated with achieving an excellent response (ACR Pedi 90), while younger age and no concurrent corticosteroid also were independently associated with achieving minimal disease activity (OR 0.60 and OR 0.57, respectively).

“The finding of a greater response in younger children and those with a history of CAU warrants further investigation and may relate to differences in disease phenotype, drug pharmacokinetics or adherence,” Dr. Hyrich and colleagues write. “Despite these positive outcomes, only one child in the study stopped etanercept therapy within one year due to remission.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Hyrich did not respond to an interview request by press time. The researchers reported no funding. Two coauthors reported disclosures.

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Systemic Inflammatory Syndromes Tagged With: Anti-TNF, Corticosteroid, etanercept, juvenile idiopathic arthritis (JIA), Pediatric

You Might Also Like:
  • Can IL-6 Predict Sarilumab Response?
  • Heart Rate Variability to Predict Treatment Response in Patients with RA
  • Methotrexate Halt Feasible in Some Etanercept RA Responders
  • Large Group Study of Systemic JIA Patients Provides Insight into Disease Pathology

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)